全文获取类型
收费全文 | 1488篇 |
免费 | 42篇 |
国内免费 | 19篇 |
专业分类
儿科学 | 10篇 |
妇产科学 | 3篇 |
基础医学 | 32篇 |
临床医学 | 219篇 |
内科学 | 432篇 |
皮肤病学 | 1篇 |
神经病学 | 240篇 |
特种医学 | 151篇 |
外科学 | 87篇 |
综合类 | 237篇 |
预防医学 | 24篇 |
眼科学 | 1篇 |
药学 | 94篇 |
中国医学 | 16篇 |
肿瘤学 | 2篇 |
出版年
2023年 | 17篇 |
2022年 | 32篇 |
2021年 | 51篇 |
2020年 | 52篇 |
2019年 | 50篇 |
2018年 | 63篇 |
2017年 | 41篇 |
2016年 | 30篇 |
2015年 | 59篇 |
2014年 | 126篇 |
2013年 | 96篇 |
2012年 | 67篇 |
2011年 | 74篇 |
2010年 | 72篇 |
2009年 | 74篇 |
2008年 | 78篇 |
2007年 | 91篇 |
2006年 | 80篇 |
2005年 | 49篇 |
2004年 | 45篇 |
2003年 | 29篇 |
2002年 | 37篇 |
2001年 | 32篇 |
2000年 | 39篇 |
1999年 | 28篇 |
1998年 | 25篇 |
1997年 | 30篇 |
1996年 | 22篇 |
1995年 | 8篇 |
1994年 | 14篇 |
1993年 | 7篇 |
1992年 | 9篇 |
1991年 | 1篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有1549条查询结果,搜索用时 23 毫秒
51.
Teruo Inoue Ryoichi Nishiki Manabu Kageyama Koichi Node 《Cardiovascular therapeutics》2004,22(4):320-333
Thrombolysis with conventional thrombolytic agents followed by percutaneous coronary intervention (PCI) had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant type plasminogen activator (mt‐PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase (Eisai, Co. Ltd., Tokyo, Japan) is a newly developed mt‐PA that can be administrated as a single intravenous bolus injection. We initiated a clinical trial [Combining Monteplase with Angioplasty (COMA)] to evaluate the effectiveness of monteplase followed by PCI. The AMI patients were randomly assigned to receive PCI following pretreatment with a single bolus intravenous injection of monteplase or direct PCI without monteplase. The initial coronary angiography prior to PCI showed that 36.2% of patients in the monteplase group achieved Thrombolysis in Myocardial Infarction (TIMI) 3 flow in the infarct‐related artery, compared with in only 7.9% of patients in the direct PCI group (P < 0.0001). During 24 months following PCI, major cardiac events occurred in 27.7% of patients in the monteplase + PCI group, and in 46.7% of patients in the direct PCI group without monteplase (P < 0.05). Thus, the ideal strategy for the treatment of AMI is the administration of monteplase upon arrival at a community hospital with a prompt transfer to a tertiary center for PCI. 相似文献
52.
Michał Hawranek Marek Gierlotka Damian Pres Marian Zembala Mariusz Gąsior 《JACC: Cardiovascular Interventions》2018,11(18):1885-1893
Objectives
The authors sought to compare outcomes of patients with myocardial infarction and cardiogenic shock (CS) treated with percutaneous coronary intervention (PCI) with or without intra-aortic balloon pump (IABP) support according to final epicardial flow in the infarct-related artery.Background
A routine use of IABP is contraindicated in patients with myocardial infarction and CS. There are no data regarding the subpopulation of patients who may benefit from such support besides patients with mechanical complications of myocardial infarction.Methods
Prospective nationwide registry data of patients with myocardial infarction and CS treated with PCI between 2003 and 2014 were analyzed. Patients were initially stratified into 2 groups according to final infarct-related artery Thrombolysis In Myocardial Infarction (TIMI) flow grade after PCI: those with successful primary PCI (TIMI flow grades 2 or 3) and those with unsuccessful primary PCI (TIMI flow grades 0 or 1). Outcomes of patients with or without IABP treatment in each group were analyzed and compared.Results
In the unsuccessful PCI group, patients in whom IABP was applied had lower in-hospital, 30-day, and 12-month mortality. IABP support in this group of patients was an independent predictor of lower 30-day mortality (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.59 to 0.89; p = 0.002). Conversely, in patients with successful PCI, IABP was an independent predictor of higher 30-day mortality (HR: 1.18; 95% CI: 1.08 to 1.30; p = 0.0004).Conclusions
IABP is associated with a lower risk of 30-day mortality in patients with myocardial infarction complicated by CS, in whom primary PCI was unsuccessful. 相似文献53.
肠系膜静脉血栓形成的临床特点分析 总被引:5,自引:0,他引:5
目的分析急性肠系膜静脉血栓(acute mesenteric venous thrombosis,AMVT)和慢性肠系膜静脉血栓(chronic mesenteric venous thrombosis,CMVT)的临床特点。方法对首都医科大学附属友谊医院1980年10月至2005年12月确诊的33例肠系膜静脉血栓(MVT)患者的临床资料进行了分析,并结合文献,总结MVT的临床特点和治疗方法。结果33例MVT中,慢性肠系膜静脉血栓11例,年龄32~78岁(平均46.6岁),无急腹症的表现,均是在腹部CT检查中发现肠系膜静脉血栓;另22例为AMVT患者,年龄19~75岁(平均48.9岁)。主要症状和体征为腹痛、腹胀、腹部膨隆、腹膜刺激征,呕吐68.2%(15/22),发热36.4%(8/22)。误诊率59.1%(13/22),手术治疗17例,死亡7例,治愈10例;溶栓治疗5例痊愈。结论早期腹部CT结合肠系膜上动脉造影可对早期AMVT做出正确的诊断,早期溶栓或手术治疗可以降低病死率。 相似文献
54.
目的:对脑血栓治疗中尿激酶溶栓疗法起到的临床作用进行分析探讨。方法选取2012年7月~2014年12月同期于我院进行脑血栓治疗的患者40例,将其分为实验组和对照组。对对照组患者给予低分子肝素进行治疗,对实验组患者给予尿激酶进行溶栓治疗。治疗结束之后对两组患者的治理效果及缺损评分进行比较。结果实验组的总体有效率为80.00%较对照组的60.00%具有优势,实验组缺损评分低于对照组,数据具有统计学差异(P<0.05)。结论对脑血栓患者采取尿激酶进行溶栓治疗能有效治愈患者疾病。 相似文献
55.
Pulmonary thromboembolism (PTE) is a life-threatening condition with a high early mortality rate caused by acute right ventricular failure and cardiogenic shock. We report a series of three patients who presented with acute and subacute submassive PTE. They were suc-cessfully treated by simple catheter-based mechanical thrombectomy and intrapulmonary arterial thrombolysis. Mechanical fragmentation and aspiration of thrombus was performed by commonly used J-wire, multi-purpose and Judkin Right guiding catheters and this obviated the need of specific thrombectomy devices. 相似文献
56.
目的比较静脉溶栓治疗急性脑梗死患者在二级医院与三级医院的安全性和疗效。方法前瞻性连续纳入1家二级甲等医院(北京丰台医院)2012年1月—2013年12月使用阿替普酶静脉溶栓治疗脑梗死21例,以1家三级甲等教学医院(首都医科大学宣武医院)同期收治的使用同样药物静脉溶栓65例为对照组,比较两组患者静脉溶栓安全性及疗效指标的差异。主要安全性指标为溶栓后严重不良事件(症状性脑出血和死亡)发生率,主要疗效指标为发病14 d的日常生活能力指数(BI)和出院时的改良Rankin评分(mRS)。结果 (1)主要终点指标中,研究组和对照组患者出院时mRS≤2分的比率分别为71.4%(15例)和58.5%(38例);溶栓后14d BI≥60分的比率分别为61.9%(13例)和64.6%(42例),两组差异均无统计学意义(P0.05)。(2)研究组和对照组的主要严重不良事件发生率为4.8%(1例)和6.2%(4例),差异无统计学意义(P0.05);其他次要指标,如早期再灌注率、血管再通率、溶栓后14 d神经功能改善比率和脑出血发生率差异均无统计学意义。研究组的患者转诊比率(9.5%,2例)低于对照组(27.7%,18例),但差异无统计学意义(P=0.09)。(3)研究组和对照组的院外时间延误、院内时间延误和总体时间延误,平均时间分别为(75±33)和(102±50)min、(72±41)和(111±38)min、(147±41)和(212±47)min,差异均有统计学意义(P0.01)。结论该选择的二级医院可相对安全有效地实施急性脑梗死的阿替普酶静脉溶栓治疗,同时二级医院的静脉溶栓治疗可以减少患者转诊比率和缩短就诊时间。 相似文献
57.
58.
《JACC: Cardiovascular Interventions》2014,7(9):969-980
ObjectivesThis study sought to evaluate in-hospital outcomes and 3-year mortality of patients presenting with unprotected left main stem occlusion (ULMSO) treated with primary percutaneous coronary intervention (PPCI).BackgroundLimited data exists about management and outcome following presentation with ULMSO.MethodsFrom January 1, 2007 to December 21, 2012, 446,257 PCI cases were recorded in the British Cardiovascular Intervention Society database of all PCI cases in England and Wales. Of those, 568 were patients having emergency PCI for ST-segment elevation infarction (0.6% of all PPCI) who presented with ULMSO (TIMI [Thrombolysis In Myocardial Infarction] flow grade 0/1 and stenosis >75%), and they were compared with 1,045 emergency patients treated with nonocclusive LMS disease. Follow-up was obtained through linkage with the Office of National Statistics.ResultsPresentation with ULMSO, compared with nonocclusive LMS disease, was associated with a doubling in the likelihood of periprocedural shock (57.9% vs. 27.9%; p < 0.001) and/or intra-aortic balloon pump support (52.5% vs. 27.2%; p < 0.001). In-hospital (43.3% vs. 20.6%; p < 0.001), 1-year (52.8% vs. 32.4%; p < 0.001), and 3-year mortality (73.9% vs 52.3%, p < 0.001) rates were higher in patients with ULMSO, compared with patients presenting with a patent LMS, and were significantly influenced by the presence of cardiogenic shock. ULMSO and cardiogenic shock were independent predictors of 30-day (hazard ratio [HR]: 1.61 [95% confidence interval (CI): 1.07 to 2.41], p = 0.02, and HR: 5.43 [95% CI: 3.23 to 9.12], p<0.001, respectively) and 3-year all-cause mortality (HR: 1.52 [95% CI: 1.06 to 2.17], p = 0.02, and HR: 2.98 [95% CI: 1.99 to 4.49], p < 0.001, respectively).ConclusionsIn patients undergoing PPCI for ULMSO, acute outcomes are poor and additional therapies are required to improve outcome. However, long-term outcomes for survivors of ULMSO are encouraging. 相似文献
59.
《JACC: Cardiovascular Interventions》2014,7(10):1093-1102
ObjectivesThe aim of this study was to identify clinical, procedural, and angiographic correlates of late/very late drug-eluting stent (DES) thrombosis as well as to determine the clinical outcomes of these events.BackgroundLate/very late DES thromboses are a poorly studied phenomenon, partly due to the relative infrequency of these events, even in large cohort studies.MethodsIn the DESERT (International Drug-Eluting Stent Event Registry of Thrombosis), a retrospective, case-control registry, 492 cases of late/very late definite DES thrombosis from 21 international sites were matched in a 1:1 fashion with controls without stent thrombosis (ST). Controls were matched according to 2 criteria: same enrolling institution and date of initial DES implantation. Baseline and procedural variables were collected, and clinical follow-up was obtained for patients with ST as long as 1 year after the event. Offline quantitative coronary angiography was performed for a subset of 378 case-control pairs.ResultsThe majority of ST events occurred after 1 year (75%) and continued to occur for as long as 7.3 years. The clinical presentation of late/very late ST events was mainly myocardial infarction (66.7% ST-segment elevation myocardial infarction and 22.0% non–ST-segment elevation myocardial infarction); in-hospital mortality was 3.8%. A minority of patients (30%) with ST were receiving dual-antiplatelet therapy at the time of the event. Independent clinical correlates of late/very late ST were younger age, African-American race, current smoking, multivessel disease, longer stented length, overlapping stents, and percutaneous coronary intervention of vein graft lesions. Independent angiographic correlates for late/very late ST were lesions within the left anterior descending artery or a bypass graft, thrombus, and a larger residual diameter stenosis after the initial DES implantation. Despite the large sample of ST cases, all identified correlates of late/very late ST had weak associations with subsequent ST (all odds ratios <2.5).ConclusionsDespite a large sample of ST cases and use of limited matching to maximize the identification of predictive factors associated with late/very late ST, the variables associated with the development of late/very late ST were only weakly predictive of subsequent events. Additionally, a relatively low observed mortality rate of ST in this series may reflect a different pathophysiology of these late/very late events compared with acute/subacute ST. (Drug Eluting Stent Registry of Thrombosis [DESERT]; NCT00812552). 相似文献
60.